helping to deliver
The right treatment, to the right patient, at the right time.
PredictImmune is a global biotechnology company. Our technology is the result of over 15 years’ research at the University of Cambridge and guides personalised treatment of patients with immune-mediated diseases.
We are developing tools to enable better disease management and an improved quality of life for patients with chronic diseases including inflammatory bowel disease (IBD) and multiple sclerosis (MS). Our first product – PredictSURE IBD™ – a prognostic test for both Crohn’s disease (CD) and ulcerative colitis (UC) is now available.
Latest news, blog & events
PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE IBD™
PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE IBD™Cambridge, UK, 02 February: PredictImmune,...
PredictSURE IBD™ and the PROFILE trial - a patient perspectiveLouise Hunt, Young Crohn’s Imagine this situation, you get diagnosed with a lifelong...
PredictImmune presenting at BSG Campus (21 - 29th January) Session Details Poster Session 1 - IBD, Pancreas & Neuroendocrine, paper number 74...